Human Atherosclerotic Plaque Inflammation Imaged Using PDG-PET/CT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

14 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-03-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People with diabetes are at increased risk for atherosclerosis and have high CVD morbidity and mortality rates. Tools for detecting and quantifying atherosclerotic pro/regression in people with diabetes and other CVD risk factors lack sensitivity and specificity for molecular level events that occur during the early stages of atherogenesis. Inflammatory macrophage infiltration in the vessel endothelium is an early, molecular level proatherogenic event. Activated macrophages consume glucose at a high rate. Novel in vivo radiotracer PET/CT techniques have been developed to detect, image and quantify molecular level events like macrophage inflammation and glucose utilization (18FDG) in human vessels. We propose to develop and test this novel technique in the Center for Clinical Imaging Research (CCIR) at WUMS. We propose that HIV-infected people with significant CVD risk profiles are a suitable, unique human model for testing these novel imaging techniques. HIV-infected people taking anti-HIV medications develop insulin resistance, T2DM, dyslipidemia, central adiposity, and hypertension. HIV replicates in macrophages and represents a chronic proinflammatory condition. Recent data indicate that HIV+ CVD risk have greater risk for atherosclerosis and MI than HIV-negative people. To test feasibility, we hypothesize that: a.18FDG-PET/CT imaging will detect more macrophage glucose uptake and inflammation in the carotid and aorta arteries of HIV-infected people with CVD risk than in HIV-negative controls; b. radiotracer PET/CT measures of proatherogenic processes will correlate with carotid intima media thickness; a standard measure of carotid atherosclerotic burden. We propose to obtain pilot data that shows feasibility for a novel analytical approach that will expand capabilities for researchers interested in studying the links between diabetes, inflammation, and CVD in humans.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Selective PET Imaging of Astrocytes and Microglia in Alzheimer's Disease

NCT05582200

Alzheimer Disease Healthy

RECRUITING

Imaging Inflammation in Alzheimer's Disease

NCT02831283

Alzheimer's Disease

COMPLETED PHASE2

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

NCT03958630

Dementia

TERMINATED PHASE1

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

NCT01680588

Alzheimer Disease

UNKNOWN PHASE2

FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis

NCT05000138

Giant Cell Arteritis Vasculitis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance Atherosclerosis Cardiovascular Disease HIV/AIDS HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-seronegative with no CVD risk factors

Healthy, 35-60 yr old HIV-seronegative men and women with no CVD risk factors (normal fasting glucose tolerance, normal fasting lipid/lipoprotein levels, normotensive, waist circumference \<102cm (men) and \<88cm (women).

No interventions assigned to this group

HIV+ with CVD risk factors

35-60 yr old HIV-infected men and women with insulin resistance, dyslipidemia, hypertension, and central adiposity.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* confirmed HIV+ status
* 35-60 years old
* stable ART for at least the past 4 mos
* CD4 count \>200 cells/µL
* HIV RNA \<40copies/mL
* fasting glucose=100-126 mg/dL
* 2hr-oGTT glucose=140-200mg/dL
* fasting triglycerides \>150mg/dL
* HDL-cholesterol \<40mg/dL (men), \<50mg/dL (women)
* resting blood pressure\>130/85mmHg
* waist circumference \>102cm(men), \>88cm(women)
* BMI 25-35 kg/m2

For HIV-negative control group:

* Confirmed HIV negative status
* 35-60 years old
* fasting glucose\<100mg/dL,
* 2hr-oGTT glucose\<140mg/dL
* fasting triglycerides\<150mg/dL
* HDL-cholesterol \>40mg/dL (men), \>50mg/dL(women)
* normal BP (\<130/85mmHg)
* no central adiposity (waist circ.\<102cm(men), \<88cm(women)
* BMI (25-35 kg/m2)

Exclusion Criteria

* history of heart disease, MI, stroke, transient ischemic attack, kidney or liver disease (active hepatitis B or C), dementia
* statins, fibrates, TZDs, antihypertensives, low dose aspirin, or other prescribed/over-the-counter agents with anti-inflammatory properties
* cocaine and methamphetamine users
* serum creatinine \>1.5 mg/dL
* pregnant women
* cognitive impairment that limits ability to provide voluntary informed consent

Minimum Eligible Age

35 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes